- Home
- BUJA vs CTSO Comparison
BUJA vs CTSO Comparison
Compare BUJA & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BUJA
- CTSO
- Stock Information
- Founded
- BUJA 2022
- CTSO 1997
- Country
- BUJA Malaysia
- CTSO United States
- Employees
- BUJA N/A
- CTSO N/A
- Industry
- BUJA Blank Checks
- CTSO Medical/Dental Instruments
- Sector
- BUJA Finance
- CTSO Health Care
- Exchange
- BUJA Nasdaq
- CTSO Nasdaq
- Market Cap
- BUJA 54.3M
- CTSO 57.2M
- IPO Year
- BUJA 2023
- CTSO N/A
- Fundamental
- Price
- BUJA $10.99
- CTSO $0.90
- Analyst Decision
- BUJA
- CTSO Strong Buy
- Analyst Count
- BUJA 0
- CTSO 3
- Target Price
- BUJA N/A
- CTSO $4.67
- AVG Volume (30 Days)
- BUJA 4.1K
- CTSO 155.7K
- Earning Date
- BUJA 01-01-0001
- CTSO 11-07-2024
- Dividend Yield
- BUJA N/A
- CTSO N/A
- EPS Growth
- BUJA N/A
- CTSO N/A
- EPS
- BUJA N/A
- CTSO N/A
- Revenue
- BUJA N/A
- CTSO $37,739,531.00
- Revenue This Year
- BUJA N/A
- CTSO $13.09
- Revenue Next Year
- BUJA N/A
- CTSO $15.68
- P/E Ratio
- BUJA $30.09
- CTSO N/A
- Revenue Growth
- BUJA N/A
- CTSO 1.80
- 52 Week Low
- BUJA $10.32
- CTSO $0.70
- 52 Week High
- BUJA $12.18
- CTSO $2.15
- Technical
- Relative Strength Index (RSI)
- BUJA 66.75
- CTSO 42.35
- Support Level
- BUJA $10.95
- CTSO $0.71
- Resistance Level
- BUJA $10.98
- CTSO $0.99
- Average True Range (ATR)
- BUJA 0.00
- CTSO 0.10
- MACD
- BUJA -0.00
- CTSO 0.01
- Stochastic Oscillator
- BUJA 100.00
- CTSO 51.39
About BUJA Bukit Jalil Global Acquisition 1 Ltd.
Bukit Jalil Global Acquisition 1 Ltd is a blank check company.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales, Distributors/strategic partners, and Government segments. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.